Rare Genetic Variants Identified in Algerian Parkinson's Study
Algerian researchers have identified rare genetic variants associated with Parkinson's disease, creating a foundational genetic map for the North African population and advancing medical research. This work provides critical insights into the genetic architecture of the condition in an underrepresented region.

Algerian researchers have published a significant study detailing the genetic diversity of Parkinson's disease within the Algerian population. The research, which aimed to establish a foundational genetic map for a region historically underrepresented in global genomic databases, was conducted using samples from 19 patients with clinically confirmed idiopathic Parkinson's disease. These patients were recruited from the Department of Medical Neurology at the CHU of Batna between July and November 2024. Genetic sequencing was performed at the Gene Life Science laboratory in Sidi Bel Abbès, Algeria.
The comprehensive analysis identified a total of 73 variants distributed across 22 genes among the patients. Notably, the study highlighted six candidate genes—DDOST, AUP1, SNORD66, TRPM7, ORC6, and GLUD2—for which no established causal link to Parkinson's disease had been previously reported in North African literature. Among these, the missense variant c.1492T > G in the GLUD2 gene was detected in four patients with late-onset Parkinson's, classified as pathogenic by ClinVar. Additionally, a missense variant c.4445 C > T in the TRPM7 gene was found in three patients and is referenced as a risk factor.
Despite a small sample size and the absence of a control cohort, this study marks a vital step in understanding the genetic landscape of Parkinson's disease in Algeria. The findings suggest potential new research avenues that could expand knowledge of the disease's genetic architecture. This work establishes a foundational resource for the North African population and underscores the importance of integrating Maghrebian cohorts into global genomic medicine, providing a framework for further investigation into pathophysiological pathways relevant to dopaminergic neurodegeneration.




